# US 2021/0171955 A1 · ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171955 A1
- Document ID: US20210171955A1
- Status: Published application
- Kind: A1
- Application number: 17/158,375
- Filed: 2021-01-26
- Published: 2021-06-10
- Earliest claimed: 2011-06-21
- Assignees: Alnylam Pharmaceuticals, Inc.
- Applicants: Alnylam Pharmaceuticals, Inc.
- Inventors: Brian Bettencourt; William Querbes; Kevin Fitzgerald; Maria Frank-Kamenetsky; Stuart Milstein; Svetlana Shulga-Morskaya
- Web page: https://patentgrep.com/patent/US20210171955A1

## CPC

- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 3/06: Antihyperlipidemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/351: Conjugate
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

## Claims

### Claim 1

A double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of Angiopoietin-like 3 (ANGPTL3), comprising a sense strand and an antisense strand,
wherein the antisense strand comprises at least 17 contiguous nucleotides which differ by no more than three nucleotides from the nucleotide sequence of 5′-AAAGACUGAUCAAAUAUGUUGAG-3′ (nucleotides 274-296 of SEQ ID NO:1),
wherein each strand is independently 17-25 nucleotides in length,
wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand are modified nucleotides,
wherein the antisense strand comprises at least seven 2′-fluoro modified nucleotides, and
wherein a ligand comprising an N-acetylgalactosamine (GalNAc) derivative is conjugated to at least one strand of the dsRNA agent.

### Claim 2 (depends on 1)

The dsRNA agent of claim 1, wherein at least one of the seven 2′-fluoro modified nucleotides is a 2′-fluoro modified guanosine nucleotide.

### Claim 3 (depends on 1)

The dsRNA agent of claim 1, wherein at least four of the seven 2′-fluoro modified nucleotides are 2-fluoro modified uridine nucleotides.

### Claim 4 (depends on 1)

The dsRNA agent of claim 1, wherein the antisense strand comprises at least ten 2′-O-methyl modified nucleotides.

### Claim 5 (depends on 1)

The dsRNA gent of claim 1, wherein the sense strand comprises at least 15 contiguous nucleotides of the nucleotide sequence 5′-AACAUAUUUGAUCAGUCUUUU-3′ (SEQ ID NO: 303).

### Claim 6 (depends on 5)

The dsRNA agent of claim 5, wherein the sense strand comprises at least one 2′-fluoro modified nucleotide.

### Claim 7 (depends on 6)

The dsRNA agent of claim 6, wherein the at least one 2′-fluoro modified nucleotide is a 2-fluoro modified uridine nucleotide.

### Claim 8 (depends on 1)

The dsRNA agent of claim 1, wherein the sense strand comprises at least six 2′-O-methyl modified nucleotides.

### Claim 9 (depends on 8)

The dsRNA agent of claim 8, wherein at least three of the six 2′-O-methyl modified nucleotides are 2′-O-methyl modified adenosine nucleotides.

### Claim 10 (depends on 8)

The dsRNA agent of claim 8, wherein at least two of the six 2′-O-methyl modified nucleotides are 2′-O-methyl modified uridine nucleotides.

### Claim 11 (depends on 10)

The dsRNA agent of claim 10, wherein one of the 2′-O-methyl modified uridine nucleotides is at position 12 of the sense strand, counting from the 5′-end of the sense strand.

### Claim 12

A double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of Angiopoietin-like 3 (ANGPTL3), comprising a sense strand and an antisense strand,
wherein the antisense strand comprises at least 17 contiguous nucleotides which differ by no more than three nucleotides from the nucleotide sequence of 5′-AAGACUGAUCAAAUAUGUUGAGU-3′ (nucleotides 273-295 of SEQ ID NO:1),
wherein each strand is independently 17-25 nucleotides in length,
wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand are modified nucleotides,
wherein the antisense strand comprises at least nine 2′-fluoro modified nucleotides, and
wherein a ligand comprising an N-acetylgalactosamine (GalNAc) derivative is conjugated to at least one strand of the dsRNA agent.

### Claim 13 (depends on 12)

The dsRNA agent of claim 12, wherein the sense strand comprises at least 15 contiguous nucleotides of the nucleotide sequence 5′-UCAACAUAUUUGAUCAGUCUU-3′ (SEQ ID NO: 358).

### Claim 14 (depends on 13)

The dsRNA agent of claim 13, wherein the sense strand comprises at least seven 2′-O-methyl modified nucleotides.

### Claim 15 (depends on 14)

The dsRNA agent of claim 14, wherein the seven 2′-O-methyl modified nucleotides are at positions 2, 4, 6, 12, 14, 16, and 18 of the sense strand, counting from the 5′-end of the sense strand.

### Claim 16 (depends on 15)

The dsRNA agent of claim 15, wherein the 2′-O-methyl modified nucleotide at positions 2 of the sense strand, counting from the 5′-end of the sense strand is a 2′-O-methyl modified cytosine nucleotide.

### Claim 17 (depends on 15)

The dsRNA agent of claim 15, wherein the 2′-O-methyl modified nucleotide at position 6 of the sense strand, counting from the 5′-end of the sense strand is a 2′-O-methyl modified adenosine nucleotide.

### Claim 18 (depends on 1)

The dsRNA agent of claim 1, wherein each strand is independently 19-25 nucleotides in length.

### Claim 19 (depends on 1)

The dsRNA agent of claim 1, wherein the dsRNA agent comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.

### Claim 20 (depends on 1)

The dsRNA agent of claim 1, wherein the GalNAc (N-acetylgalactosamine) derivative is attached through a bivalent or trivalent branched linker.

### Claim 21 (depends on 1)

The dsRNA agent of claim 1, wherein the sense and antisense strands comprise nucleotide sequences selected from the group consisting of
(SEQ ID NO: 387)
5′-CAUAUUUGAUCAGUCUUUUUA-3′
and
(SEQ ID NO: 572)
5′-UAAAAAGACUGAUCAAAUAUGUU-3′;
(SEQ ID NO: 287)
5′-ACAUAUUUGAUCAGUCUUUUU-3′
and
(SEQ ID NO: 472)
5′-AAAAAGACUGAUCAAAUAUGUUG-3′;
(SEQ ID NO: 303)
5′-AACAUAUUUGAUCAGUCUUUU-3′
and
(SEQ ID NO: 488)
5′-AAAAGACUGAUCAAAUAUGUUGA-3′;
(SEQ ID NO: 39)
5′-ACAUAUUUGAUCAGUCUUU-3′
and
(SEQ ID NO: 101)
5′-AAAGACUGAUCAAAUAUGU-3′;
(SEQ ID NO: 294)
5′-CAACAUAUUUGAUCAGUCUUU-3′
and
(SEQ ID NO: 479)
5′-AAAGACUGAUCAAAUAUGUUGAG-3′;
(SEQ ID NO: 358)
5′-UCAACAUAUUUGAUCAGUCUU-3′
and
(SEQ ID NO: 543)
5′-AAGACUGAUCAAAUAUGUUGAGU-3′;
and
(SEQ ID NO: 64)
5′-CAACAUAUUUGAUCAGUCU-3′
and
(SEQ ID NO: 126)
5′-AGACUGAUCAAAUAUGUUG-3′

### Claim 22 (depends on 1)

A cell containing the dsRNA agent of claim 1.

### Claim 23 (depends on 1)

A pharmaceutical composition for inhibiting expression of an ANGPTL3 gene, comprising the dsRNA agent of claim 1.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23, wherein the dsRNA agent is present in a buffered solution.

### Claim 25 (depends on 12)

The dsRNA agent of claim 12, wherein each strand is independently 19-25 nucleotides in length.

### Claim 26 (depends on 12)

The dsRNA agent of claim 12, wherein the dsRNA agent comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.

### Claim 27 (depends on 12)

The dsRNA agent of claim 12, wherein the GalNAc (N-acetylgalactosamine) derivative is attached through a bivalent or trivalent branched linker.

### Claim 28 (depends on 12)

A cell containing the dsRNA agent of claim 12.

### Claim 29 (depends on 12)

A pharmaceutical composition for inhibiting expression of an ANGPTL3 gene, comprising the dsRNA agent of claim 12.

### Claim 30 (depends on 29)

The pharmaceutical composition of claim 29, wherein the dsRNA agent is present in a buffered solution.
